CLINICAL TRIALS PROFILE FOR TALIMOGENE LAHERPAREPVEC
✉ Email this page to a colleague
All Clinical Trials for talimogene laherparepvec
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00289016 ↗ | A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma | Completed | Symbion Research International | Phase 2 | 2005-12-01 | The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates. |
| NCT00289016 ↗ | A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma | Completed | BioVex Limited | Phase 2 | 2005-12-01 | The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates. |
| NCT01161498 ↗ | Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer | Terminated | Amgen | Phase 3 | 2011-02-01 | This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the tumours versus the use of chemoradiation alone. This study may provide information on the usefulness of talimogene laherparepvec combined with chemoradiation as a future treatment for head and neck cancer. |
| NCT01161498 ↗ | Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer | Terminated | BioVex Limited | Phase 3 | 2011-02-01 | This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the tumours versus the use of chemoradiation alone. This study may provide information on the usefulness of talimogene laherparepvec combined with chemoradiation as a future treatment for head and neck cancer. |
| NCT01368276 ↗ | An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma | Completed | BioVex Limited | Phase 3 | 2010-10-01 | The purpose of this study is to learn about the safety and the risks of using talimogene laherparepvec in patients who already received treatment with talimogene laherparepvec in study 005/05 (NCT00769704), and to see if extended treatment with talimogene laherparepvec can destroy melanoma tumors. |
| NCT01740297 ↗ | Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | Completed | Amgen | Phase 1/Phase 2 | 2013-02-07 | Phase 1b of the study will evaluate the safety of talimogene laherparepvec in combination with ipilimumab. Phase 2 is a randomized study that will evaluate the safety and efficacy of talimogene laherparepvec in combination with ipilimumab versus ipilumumab alone. |
| NCT02014441 ↗ | Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec | Completed | Amgen | Phase 2 | 2014-04-07 | The primary objective was to estimate the proportion of participants with detectable talimogene laherparepvec deoxyribonucleic acid (DNA) in the blood and urine at any time after administration of talimogene laherparepvec within the first 3 cycles. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for talimogene laherparepvec
Condition Name
Clinical Trial Locations for talimogene laherparepvec
Trials by Country
Clinical Trial Progress for talimogene laherparepvec
Clinical Trial Phase
Clinical Trial Sponsors for talimogene laherparepvec
Sponsor Name
